



DAU

Drugs of Abuse in Urine

lgcstandards.com/AXIO

ISO/IEC 17043 | ISO 9001



29821

DAU

Drugs of Abuse in Urine

The LGC AXIO PT Drugs of Abuse in Urine (DAU) scheme is designed to provide an independent performance assessment of laboratories and clinics that provide routine services for detection of drugs of abuse in urine.

Human urine has been used for many years to detect the presence of illicit drugs. Urine testing may be requested for a variety of reasons, including health care, occupational monitoring, insurance screening, legal and forensic purposes. Errors in tests could have severe consequences, such as dismissal from work or miscarriage of justice.

Laboratories and clinics are encouraged to participate in suitable PT/EQA schemes to ensure the highest standard of drug testing is achieved through independent assessment of measurement quality.

The operation of the DAU scheme is supported by an Advisory Group consisting of members of professional bodies, scheme participants, and others experienced in the field. The scheme reports on the performance of U.K. participants (who have clinical responsibilities) to the National Quality Assurance Advisory Panels for Chemical Pathology.

DAU

Drugs of Abuse in Urine

Test Material*	Analyte*
Urine test materials obtained from volunteers & known drug users which regularly contain mixtures of drugs & their metabolites	Amfetamines and stimulants, Cannabinoids, Cocaine and metabolites, Ethyl glucuronide, Ethyl sulfate, Gamma-Hydroxybutyrate (GHB), Minor tranquillizers, Non-opiate narcotics, Opiates. Other current drugs and/or metabolites may also be included.

* The full range and availability of test materials and analytes is determined on an annual basis and may be added or removed. For accredited and non-accredited status please see current application form/scheme description.

